Daily News: FDA Approves New Drug to Treat Psoriasis
Saturday October 31, 2009
Print This- Select Text Size:
Comments
advertisement
Ustekinumab is administered subcutaneously as a weight-based dose. For patients weighing less than 100 kg (220 lbs), the recommended dose is 45 mg initially and four weeks later, followed by 45 mg every 12 weeks. For patients weighing >100 kg (220 lbs), the recommended dose is 90 mg initially and 4 weeks later, followed by 90 mg every 12 weeks.
The most common adverse reactions reported include nasopharyngitis, upper respiratory tract infection, headache, and fatigue. Adverse drug reactions may also occur at the site of administration including cellulitis, pain, swelling, pruritus, induration, hemorrhage, bruising, and irritation.
Because ustekinumab reduces the immune system’s ability to fight infections, it poses a risk of infection. Serious infections have been reported with ustekinumab, some leading to hospitalization. These infections were caused by viruses, fungi, or bacteria that have spread throughout the body. There may also be an increased risk of developing cancer, and ongoing studies are evaluating this risk. Before initiation of therapy, patients should be evaluated for tuberculosis and, if indicated, treated with antitubercular drug therapy before initiating ustekinumab therapy.
Ustekinumab therapy complicates vaccination administration. Non-live vaccines may be ineffective when administered during treatment. Patients receiving ustekinumab therapy must not, however, receive any live vaccines, nor should their household contacts because of the potential risk for shedding from the household contact and transmission to patient.
To comment, e-mail editorNTL@gannetthg.com.
Reader Comments
Login
Be the first to comment!